Search results
Oculis sees promise in dry eye disease subgroup, plans phase 3
FierceBiotech· 3 days agoOculis is forging ahead with its precision medicine approach to treating dry eye disease, outlining...
BioRestorative Therapies maintains its 'Buy' rating and $15 target price By Investing.com
Investing.com· 23 hours agoThe firm highlighted the company's solid financial standing, with $16.4 million in cash reserves at...
CollPlant prints commercial-size regenerative breast implants By Investing.com
Investing.com· 6 days agoCollPlant Biotechnologies (NASDAQ:CLGN), an innovator in regenerative and aesthetic medicine, has...
Calico Life Sciences Announces that Fosigotifator (ABBV-CLS-7262) for Vanishing White Matter Disease...
KNDO - KNDU Tri-Cities· 6 days agoFosigotifator is being developed by Calico and AbbVie pursuant to their 2014 collaboration as a potential treatment for Vanishing White Matter (VWM) disease. FDA's Center ...
More Tender Than Swollen Joints Worsen Outcomes in Early RA
Medscape· 7 days agoPatients with early rheumatoid arthritis who had higher tender-swollen joint differences showed...
Moderna's MMA candidate nabs spot in FDA pilot for rare disease drugs
FierceBiotech· 6 days agoModerna’s methylmalonic acidemia candidate, mRNA-3705, will be developed under the FDA’s START pilot...
Once-Weekly Somapacitan Remains Safe, Effective Long-Term
Medscape· 7 days agoGrowth improvements were similar between children taking somapacitan for 3 years and those who...
Seladelpar Shows Clinically Meaningful Improvements in PBC
Medscape· 3 days agoThe first analysis of 337 patients with PBC, with and without cirrhosis, showed that treatment with seladelpar had a durable effect up to 2 years on cholestasis and markers of liver injury, ...
REGENXBIO Announces Leadership Transition
NBC 17 Raleigh· 1 day agoREGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective ...
These Biotech Stocks Hit New Highs, Did You Reap The Rewards?
RTT News· 6 days agoProtagonist is a clinical-stage biopharmaceutical company with multiple assets having billion-dollar market potential. The company has a worldwide license and collaboration agreement with Takeda ...
